You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

Certaines de ces informations ou toutes, dans certains cas, n’apparaissent qu’en Anglais. Vous pouvez demander la version française

Funded Evidence-Informed Regimens

Drug and regimen monographs and information sheets for patients provide information on dosing and administering cancer treatment protocols. They are for general reference and are not meant to replace prescribing information or physician recommendations.

If you have questions about ST-QBP funding on our website, please visit our Frequently Asked Questions page.

Find enhanced Regimen Patient Information Sheets, created in collaboration with patient and family advisors.

Regimens

12 Items
Cancer Type: Skin, Melanoma     
Intent: Palliative
Funding:
Exceptional Access Program
    daBRAfenib - As monotherapy for the first-line and second-line treatment of patients with BRAF V600 mutation-positive unresectable melanoma or metastatic disease, according to specific criteria
May 2019
Cancer Type: Skin, Melanoma     
Intent: Palliative
Funding:
Exceptional Access Program
    daBRAfenib - In combination with trametinib for the treatment of BRAF V600 mutation-positive, unresectable or metastatic melanoma, according to specific clinical criteria
Exceptional Access Program
    trametinib - In combination with dabrafenib for the treatment of BRAF V600 mutation-positive, unresectable or metastatic melanoma, according to specific clinical criteria
May 2019
Cancer Type: Lung, Non-Small Cell     
Intent: Palliative
Drugs Used:
daBRAFenib (Unfunded),
trametinib (Unfunded)
May 2019
Cancer Type: Skin, Melanoma     
Intent: Adjuvant, Curative
Drugs Used:
daBRAFenib (Unfunded),
trametinib (Unfunded)
May 2019
Cancer Type: Hematologic, Leukemia - Chronic Myeloid (CML)     
Intent: Palliative
Funding:
Exceptional Access Program
    daSAtinib - Ph+ CML in the chronic phase, with specific criteria
Exceptional Access Program
    daSAtinib - Accelerated phase or blast phase Ph+ CML with documented resistance or intolerance to imatinib, with specific criteria
May 2019
Cancer Type: Hematologic, Leukemia - Acute Lymphoblastic (ALL)     
Intent: Curative, Palliative
Funding:
Exceptional Access Program
    daSAtinib - PH+ ALL, with specific criteria
May 2019
Cancer Type: Gynecologic, Gestational Trophoblastic Disease     
Intent: Curative
May 2019
Cancer Type: Sarcoma, Wilm's Tumour     
Intent: Adjuvant, Palliative
May 2019
Cancer Type: Gynecologic, Gestational Trophoblastic Disease     
Intent: Curative
Jun 2019
Cancer Type: Gynecologic, Gestational Trophoblastic Disease     
Intent: Curative
Jun 2019
Cancer Type: Sarcoma, Ewing's     
Intent: Neoadjuvant, Adjuvant, Palliative
May 2019
Cancer Type: Sarcoma, Soft Tissue     
Intent: Neoadjuvant, Adjuvant, Palliative
May 2019